Study Shows an Aspirin a Day Reduces Melanoma Risk
Long-term use of anti-inflammatory drugs provide prevention hope
For years, doctors have been prescribing a daily dose aspirin to lower the risk of heart attack and stroke. More recently aspirin has proven effective in lowering the risk of colon cancer. A new study from researchers at
Beth Israel Deaconess Medical Center and the
Dana-Farber Cancer Institute suggests that long-term aspirin use may also significantly lower the risk of cutaneous melanoma (CM), the most deadly form of skin cancer.
"The incidence of cutaneous melanoma continues to climb faster than other common cancers," said senior author
Dr. Robert Stern, Chief of
Dermatology at BIDMC. "Prevention strategies other than sunscreen and reduced sun exposure may help reduce this incidence."
The research team analyzed data to assess cutaneous melanoma risk in association with the long-term use of lipid-lowering agents (LLAs), or statins, and non-steroidal anti-inflammatory drugs (NSAIDs) including acetylsalicylic acid (ASA), or aspirin. The results published in the Journal of Investigative Dermatology show while the use of statins shows no significant protective benefit, the "continuous use of ASA for five years or more reduces the CM risk by almost half."
In total, 400 melanoma patients participated in the study. Information collected from the melanoma patients was compared with a 600 person control group. The groups were "matched for age, gender, and community." They were asked about previous and current medication use and risk factors for melanoma such as sun exposure history and ease of sun burning.
"Our data supports the idea that, in particular, the long-term use of aspirin has a protective effect," said Stern. "It's possible that long-term use of non-ASA NSAIDs could also reduce risk, but because non-ASA NSAIDs like ibuprofen and naproxen are generally taken with less regularity than aspirin, the power to detect a significant association is limited. This study adds another health benefit for the regular use of aspirin in many populations, especially those for whom aspirin is likely to reduce the risk of heart attack and stroke."
Co-authors include first author Dr. Clara Curiel-Lewandrowski, (formerly of BIDMC's Department of Hematology-Oncology, currently on faculty at the Arizona Cancer Center),
Dr. Michael Atkins of BIDMC's
Department of Hematology-Oncology, and Maria Gomez of the BIDMC
Department of Dermatology; and Tamar Nijsten and Loes Hollestein, both of Erasmus Medical Center, Rotterdam, The Netherlands.
This research was supported by funding from the Harry Lloyd Charitable Trust, the Melanoma Foundation of New England, Kokos Research Fund, Harvard SPORE in Skin Cancer, and the Alan and Janice Levin Endowed Chair in Cancer Research at the University of Arizona.
Above content provided by Beth Israel Deaconess Medical Center. For advice about your medical care, consult your doctor.
Posted September 2011